BioXcel Therapeutics, Inc. announced that it will present a late breaking poster featuring data from a preclinical study of the Company’s BXCL701 and an OX40-agonist antibody as a potential combination therapy for treatment of certain solid tumors at the upcoming American Association for Cancer Research Annual Meeting 2019 being held from March 29 to April 3, 2019 in Atlanta, Georgia.
March 12, 2019
· 4 min read